ReviewInternational journal of nanomedicine2024
Transforming Cancer Treatment with Nanotechnology: The Role of Berberine as a Star Natural Compound.
Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Salvianolic acid monomers against metastasis: Decoding the multilayered interception of EMT, angiogenesis and immune evasion (Review).International journal of molecular medicine · 2026Review
- A berberine-functionalized green silver nanoplatform for combined chemo-photodynamic therapy against breast cancer cells.Nanoscale advances · 2026Article
- Traditional Chinese Medicine-derived berberine-loaded herbzyme ameliorates ulcerative colitis by regulating IL10 and TMAO.Materials today. Bio · 2026Article
- Cellular and Molecular Mechanisms of Berberine in Cancer Therapy: Recent Advances.Archiv der Pharmazie · 2026Review
- Genome-wide CRISPR screening identifiesOncology letters · 2026Article
- PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics.Frontiers in oncology · 2026Review
- Berberine-induced ferroptosis as a novel anti-cancer strategy: Molecular, epigenetic and translational perspectives.EXCLI journal · 2026Review
- TRAIL of Hope: Bioactive Dietary Component-Driven Carrier-Free Nanoplatforms for Synergistically Enhanced Tumor Multimodal Therapy.International journal of nanomedicine · 2026Review
- Interdisciplinarity traditional Chinese medicine microneedles in skin disease treatment: Recent advances and challenges.Bioactive materials · 2026Review
- Toward oral nanomaterial-based drug delivery systems for hepatocellular carcinoma therapy: evidence mapping, route-specific validation, and translational challenges.Frontiers in pharmacology · 2026Review
- Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Perovskite quantum dots in cancer diagnosis and therapy: from synthesis to biomedical applications.RSC advances · 2025Review
- In Vitro Evaluation of the Safety and Antineoplastic Effects in Gastrointestinal Tumors of Nanostructured Lipid Carriers Loaded with Berberine.Pharmaceutics · 2025Article
- Berberine and its nanoformulations and extracts: potential strategies and future perspectives against multi-drug resistant bacterial infections.Frontiers in microbiology · 2025Review
- The therapeutic potential of phytochemicals in morphine tolerance: targeting microglia-mediated neuroinflammation.Frontiers in pharmacology · 2025Review
- Application of Nanotechnology in TACE Treatment of Liver Cancer.International journal of nanomedicine · 2025Review
- Application of liposomal nanoparticles of berberine in photodynamic therapy of A549 lung cancer spheroids.Biochemistry and biophysics reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (BBR), recognized as an oncotherapeutic phytochemical, exhibits its anti-cancer properties via multiple molecular pathways. However, its clinical application is hindered by suboptimal tumor accumulation, rapid systemic elimination, and diminished bioactive concentration owing to extensive metabolic degradation. To circumvent these limitations, the strategic employment of nanocarriers and other drugs in combination with BBR is emerging as a focus to potentiate its anti-cancer efficacy. This review introduced the expansive spectrum of BBR's anti-cancer activities, BBR and other drugs co-loaded nanocarriers for anti-cancer treatments, and evaluated the synergistic augmentation of these amalgamated modalities. The aim is to provide an overview of BBR for cancer treatment based on nano-delivery. Berberine (BBR), recognized as an oncotherapeutic phytochemical, exhibits its anti-cancer properties via multiple molecular pathways. However, its clinical application is hindered by suboptimal tumor accumulation, rapid systemic elimination, and diminished bioactive concentration owing to extensive metabolic degradation. To circumvent these limitations, the strategic employment of nanocarriers and other drugs in combination with BBR is emerging as a focus to potentiate its anti-cancer efficacy. Nano-delivery systems increase drug concentration at the tumor site by improving pharmacological activity and tissue distribution, enhancing drug bioavailability. Organic nanocarriers have advantages for berberine delivery including biocompatibility, encapsulation, and controlled release of the drug. While the advantages of inorganic nanocarriers for berberine delivery mainly lie in their efficient loading ability of the drug and their slow release ability of the drug. This review introduced the expansive spectrum of BBR's anti-cancer activities, BBR and other drugs co-loaded nanocarriers for anti-cancer treatments, and evaluated the synergistic augmentation of these amalgamated modalities. The aim is to provide an overview of BBR for cancer treatment based on nano-delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.